Date: 2013-05-14
Type of information: Development agreement
Compound: RYI-008
Company: CMC Biologics (Denmark) RuiYi (China)
Therapeutic area:
Type agreement: development
Action mechanism: RYI-008, formerly ARGX-109, is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. The antibody was discovered by arGEN-X, Ghent Belgium, utilizing the arGEN-X SIMPLE AntibodyTM technology, and exclusively license to RuiYi to develop and commercialize globally.
Disease:
Details: CMC Biologics has announced the execution of an agreement with RuiYi Inc. to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody. CMC Biologics’ proprietary CHEF1® high-productivity expression plasmid will be utilized for the cell line development to optimize cell growth, and consistent, high-level protein expression in a rapid time frame. Specific terms of the agreement were not disclosed.
Financial terms:
Latest news:
